title: The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis.
abstract: The effects of daily administration of recombinant human granulocyte colony-stimulating factor (rhG-CSF) to eight normal volunteers donating granulocytes for neutropenic relatives undergoing marrow transplantation were studied. Granulocyte donors consisted of seven marrow donors (5 syngeneic, 2 HLA identical) and one haploidentical son who had not donated marrow. All donors were administered daily rhG-CSF at a mean dose of 5 micrograms/kg/d (range 3.5 to 6.0) for a mean of 11.75 days (range 9 to 14 days), and granulocytes were collected a mean of 7.6 times (range 4 to 12). RhG-CSF was well tolerated and only minor side effects were observed. All donors became anemic from marrow donation and the removal of red blood cells during the collection procedures. Red blood cell transfusions were not given. All donors had a decrease in platelet counts and the magnitude of the decrement appeared to be greater than in historical donors. This was due in part to increased removal of platelets with the collection product, but a direct effect of rhG-CSF on platelet production cannot be excluded. The mean precollection granulocyte level was 29.6 x 10(9)/L (range 11.8 to 79.8), which was a 10-fold increase over baseline. The mean number of granulocytes collected was 41.6 x 10(9) (range 1.3 to 144.1), which was a six-fold increase over historical donors not receiving rhG-CSF. The mean granulocyte level 24 hours after transfusion into neutropenic recipients was 0.95 x 10(9)/L (median 0.57 and range .06 to 9.47). This study indicates that rhG-CSF is safe to administer to normal individuals, significantly improves the quantity of granulocytes collected, and results in significant circulating levels of granulocytes in neutropenic recipients. Further studies to evaluate rhG-CSF in normal granulocyte donors are warranted.
authors.affiliation: Fred Hutchinson Cancer Research Center, Seattle, WA 98104.
authors.forename: W I
authors.initials: WI
authors.lastname: Bensinger
authors.forename: T H
authors.initials: TH
authors.lastname: Price
authors.forename: D C
authors.initials: DC
authors.lastname: Dale
authors.forename: F R
authors.initials: FR
authors.lastname: Appelbaum
authors.forename: R
authors.initials: R
authors.lastname: Clift
authors.forename: K
authors.initials: K
authors.lastname: Lilleby
authors.forename: B
authors.initials: B
authors.lastname: Williams
authors.forename: R
authors.initials: R
authors.lastname: Storb
authors.forename: E D
authors.initials: ED
authors.lastname: Thomas
authors.forename: C D
authors.initials: CD
authors.lastname: Buckner
mesh_terms: D000328:Adult; D001782:Blood Donors; D004334:Drug Administration Schedule; D004551:Elbow Joint; D004911:Erythrocyte Volume / Q000187:drug effects; D005260:Female; D005269:Femur; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000494:pharmacology*; D006098:Granulocytes / Q000637:transplantation*; D006801:Humans; D007937:Leukapheresis / Q000009:adverse effects; D007958:Leukocyte Count / Q000187:drug effects; D008297:Male; D010146:Pain / Q000209:etiology; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology
chemical_list: D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor